If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"","masked_caregiver":"","masked_investigator":"","masked_subject":"","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"","arm_groups":[],"assignment":"","brief_summary":"","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"A pilot, randomised, open-label, monocenter study to evaluate the Safety and Efficacy of a Quadruple combination therapy of triple combination tablet (Trizivir) [abacavir, lamivudine,zidovudine] plus Saquinavir- SGC/ritonavir versus Triple combination therapy of Combivir plus Saquinavir-SGC/ritonavir in treatment naive HIV-1 Infected subjects with High plasma HIV-1 RNA levels and low CD4 cell counts.","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV infections","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 21:58:31","criteria":"Inclusion Criteria:\n -\nExclusion Criteria:\n -","detailed_description":"","display_gender":"","display_gender_internal":"","display_phase":"Phase 3","display_phase_internal":"PHASE_3","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"","exclusion":"","gender":"","gender_based":"","gender_description":"","healthy_volunteers":"","id":"61f57ea7-1dcf-5110-a8a1-872cc30c8138","internal":{"content":null,"contentDigest":"1cbd8abea115188f96300bf7416a30ac","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria:\n -\nExclusion Criteria:\n -","interventions":[],"interventional_subtype":"","is_fda_regulated":null,"is_high_value":false,"is_ind_study":null,"keywords":[],"last_follow_up_date":"09/17/2002 00:00:00","links":[],"locations":[],"masking":"","maximum_age_raw":"","maximum_age":null,"minimum_age":null,"minimum_age_raw":"","modified_date":"08/01/2019 17:30:04","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A pilot, randomised, open-label, monocenter study to evaluate the Safety and Efficacy of a Quadruple combination therapy of triple combination tablet (Trizivir) [abacavir, lamivudine,zidovudine] plus Saquinavir- SGC/ritonavir versus Triple combination therapy of Combivir plus Saquinavir-SGC/ritonavir in treatment naive HIV-1 Infected subjects with High plasma HIV-1 RNA levels and low CD4 cell counts.","org_study_id":"COL30470","overall_contact":{"email":null,"last_name":null,"phone":null},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":null,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"Phase 3","primary_compl_date":null,"primary_outcomes":[],"product_name":"abacavir;lamivudine;ritonavir;saquinavir;zidovudine","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":[]},"start_date":"10/10/2000 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[{"citation":"Staszewski et al: “The QUAD Study: A Pilot-Study to Assess the Efficacy and Safety of Trizivir + RTV-Boosted Saquinavir (TZV/SQVr) Compared to Combivir + RTV-Boosted Saquinavir (CBV/SQVr) in ART-Naive Patients with High viral load (VL) and Low CD4 Count. 24 Week Interim analysis. 9th European AIDS Conference, Warsaw, 25.-29.10.2003, abstract #F1/1","is_results_ref":"","pubmed_id":""}],"is_section_801":null}},"pageContext":{"studyId":"COL30470"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}